MX2010004495A - Derivados de 2-aminooxazol como antagonistas de vanilloide-1 de receptor potencial transitorio (trpv1) utiles para tratar dolor. - Google Patents

Derivados de 2-aminooxazol como antagonistas de vanilloide-1 de receptor potencial transitorio (trpv1) utiles para tratar dolor.

Info

Publication number
MX2010004495A
MX2010004495A MX2010004495A MX2010004495A MX2010004495A MX 2010004495 A MX2010004495 A MX 2010004495A MX 2010004495 A MX2010004495 A MX 2010004495A MX 2010004495 A MX2010004495 A MX 2010004495A MX 2010004495 A MX2010004495 A MX 2010004495A
Authority
MX
Mexico
Prior art keywords
treating pain
antagonists useful
trpvl antagonists
aminooxazole
derivatives
Prior art date
Application number
MX2010004495A
Other languages
English (en)
Inventor
Anil Vasudevan
Michael E Kort
Erol K Bayburt
John R Koenig
Robert G Schmidt
Stanley Didomenico Jr
Arthur R Gomtsyan
Richard J Perner
Jerome F Daanen
Philip R Kym
Eric Voight
Original Assignee
Abbott Lab
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Abbott Lab filed Critical Abbott Lab
Publication of MX2010004495A publication Critical patent/MX2010004495A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/08—Drugs for disorders of the alimentary tract or the digestive system for nausea, cinetosis or vertigo; Antiemetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/10—Drugs for disorders of the urinary system of the bladder
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/04—Centrally acting analgesics, e.g. opioids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/06—Antimigraine agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P9/00—Drugs for disorders of the cardiovascular system
    • A61P9/10—Drugs for disorders of the cardiovascular system for treating ischaemic or atherosclerotic diseases, e.g. antianginal drugs, coronary vasodilators, drugs for myocardial infarction, retinopathy, cerebrovascula insufficiency, renal arteriosclerosis
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D263/00—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings
    • C07D263/02—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings
    • C07D263/30—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D263/34—Heterocyclic compounds containing 1,3-oxazole or hydrogenated 1,3-oxazole rings not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached to ring carbon atoms
    • C07D263/48—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
    • C07D413/04—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings directly linked by a ring-member-to-ring-member bond

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • General Chemical & Material Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Neurosurgery (AREA)
  • Neurology (AREA)
  • Pain & Pain Management (AREA)
  • Biomedical Technology (AREA)
  • Urology & Nephrology (AREA)
  • Rheumatology (AREA)
  • Heart & Thoracic Surgery (AREA)
  • Cardiology (AREA)
  • Vascular Medicine (AREA)
  • Child & Adolescent Psychology (AREA)
  • Diabetes (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Pulmonology (AREA)
  • Immunology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Hospice & Palliative Care (AREA)
  • Otolaryngology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Heterocyclic Carbon Compounds Containing A Hetero Ring Having Nitrogen And Oxygen As The Only Ring Hetero Atoms (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

Se describen compuestos de la fórmula (I), en donde R1, R2, R4, y W son como se describe en la descripción y son antagonistas de TRPV1 con penetración en el sistema nervioso central (CNS). Se describen también composiciones que comprenden dichos compuestos y métodos para tratar condiciones y trastornos utilizando dichos compuestos y composiciones. (Ver fórmula I).
MX2010004495A 2007-10-25 2008-10-25 Derivados de 2-aminooxazol como antagonistas de vanilloide-1 de receptor potencial transitorio (trpv1) utiles para tratar dolor. MX2010004495A (es)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US98249007P 2007-10-25 2007-10-25
US12/256,931 US7998993B2 (en) 2007-10-25 2008-10-23 TRPV1 antagonists
PCT/US2008/081229 WO2009055749A1 (en) 2007-10-25 2008-10-25 2-aminooxazole derivatives as trpvl antagonists useful for treating pain

Publications (1)

Publication Number Publication Date
MX2010004495A true MX2010004495A (es) 2010-05-05

Family

ID=40227493

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2010004495A MX2010004495A (es) 2007-10-25 2008-10-25 Derivados de 2-aminooxazol como antagonistas de vanilloide-1 de receptor potencial transitorio (trpv1) utiles para tratar dolor.

Country Status (10)

Country Link
US (1) US7998993B2 (es)
EP (2) EP2220059B1 (es)
JP (1) JP2011500852A (es)
CN (1) CN101835762A (es)
AT (1) ATE518846T1 (es)
CA (1) CA2702976A1 (es)
HK (1) HK1147493A1 (es)
MX (1) MX2010004495A (es)
TW (1) TW200934487A (es)
WO (1) WO2009055749A1 (es)

Families Citing this family (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20100210682A1 (en) * 2009-02-19 2010-08-19 Abbott Laboratories Repeated Dosing of TRPV1 Antagonists
US8722964B2 (en) * 2009-04-23 2014-05-13 Transposagen Biopharmaceuticals, Inc. Genetically engineered or transgenic rats exhibiting a cancer phenotype due to a disruption of germline tumor suppressor genes
US9314005B2 (en) 2009-07-01 2016-04-19 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for severe combined immunodeficiency (SCID)
EP2460016A2 (en) * 2009-07-30 2012-06-06 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for pharmacokinetics
EP2461672A2 (en) * 2009-08-05 2012-06-13 Transposagen Biopharmaceuticals, Inc. Genetically modified rat models for drug metabolism
US8602579B2 (en) 2009-09-25 2013-12-10 Cree, Inc. Lighting devices including thermally conductive housings and related structures
PT2790687T (pt) 2011-12-16 2018-11-13 Poseida Therapeutics Inc Moduladores de trpc4 para uso no tratamento ou prevenção da dor
JP6830569B1 (ja) 2019-08-23 2021-02-17 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法
WO2021039023A1 (ja) 2019-08-23 2021-03-04 持田製薬株式会社 ヘテロシクリデンアセトアミド誘導体の製造方法

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5151440A (en) 1990-02-28 1992-09-29 Allergan, Inc. Method for reducing or maintaining intraocular pressure in the mammalian eye by administering pharmaceutical compositions containing 2-(2-alkylphenylamino)-oxazolines, 2-(2-alkylphenyl-amino)-thiazolines and 2-(2-alkylphenylamino)-imidazolines
CN101248052A (zh) 2005-05-11 2008-08-20 艾博特公司 香草素受体亚型1(vr1)拮抗剂及其用途

Also Published As

Publication number Publication date
JP2011500852A (ja) 2011-01-06
US20090124666A1 (en) 2009-05-14
US7998993B2 (en) 2011-08-16
HK1147493A1 (en) 2011-08-12
EP2412372A1 (en) 2012-02-01
WO2009055749A1 (en) 2009-04-30
ATE518846T1 (de) 2011-08-15
EP2220059B1 (en) 2011-08-03
TW200934487A (en) 2009-08-16
CA2702976A1 (en) 2009-04-30
EP2220059A1 (en) 2010-08-25
CN101835762A (zh) 2010-09-15

Similar Documents

Publication Publication Date Title
MX2010004495A (es) Derivados de 2-aminooxazol como antagonistas de vanilloide-1 de receptor potencial transitorio (trpv1) utiles para tratar dolor.
MX2010007392A (es) Antagonistas de trpa1.
MX2010007391A (es) Antagonistas de trpa1.
MX2009011205A (es) Derivados de 2-iminoisotiazol como ligandos del receptor canabinoide.
MX2010003366A (es) Derivados de piperidina y piperazina para el tratamiento de tumores.
HK1188985A1 (zh) 治療細胞增殖紊亂的化合物和方法
EA201070238A1 (ru) Соединения пиримидина
WO2009023539A3 (en) Tetrahydropyridine carboxamide derivatives as trpvl antagonists
MX2010004498A (es) Derivados de ciclohexenoamida y su uso como antagonistas de trpv1.
MX2009010960A (es) Compuestos heterociclicos y sus metodos de uso.
TW200716584A (en) Dihydrobenzofuran derivatives and uses thereof
UA99936C2 (en) Biaryl substituted azabicyclic alkane derivatives
BRPI0910182A2 (pt) composto de fórmula (i), composição farmacêutica, método de tratamento de um distúrbio e uso de um composto"
GEP20084550B (en) Substituted morpholine compounds for the treatment of central nervous system disorders
MX2009012374A (es) Compuestos novedosos como ligandos del receptor de canabinoides.
UA101478C2 (ru) Соединения, полезные как ингибиторы raf-киназы
WO2007140439A3 (en) Compounds as cannabinoid receptor ligands and uses thereof
TNSN08373A1 (en) Azolopyrimidines as inhibitors of cannabinoid 1 activity
GB2466912A (en) Compositions and methods for treating lysosomal disorders
TNSN08370A1 (en) Tetrahydropyridothienopyrimidine compounds and methods of use thereof
WO2010033543A3 (en) Substituted benzamides as cannabinoid receptor ligands
TW200942535A (en) Novel compounds as cannabinoid receptor ligands
MX2009007713A (es) Derivados de piridazina, procedimientos para su preparacion y su uso como fungicidas.
MX2009010363A (es) Compuestos de 1,3-tiazol-2(3h)-ilideno como ligandos del receptor canabinoide.
WO2009046842A3 (de) Thialzolderivate zur behandlung von krebs